Centrexion Therapeutics Corporation

Boehringer Ingelheim International Gmbh

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Boehringer Ingelheim Pharma Gmbh & Co Kg

Yunhai Cui

Klaus Rudolf

Henri Doods

Riccardo Giovannini

Raimund Kuelzer

Marco Ferrara

Iain Lingard

Rocco Mazzaferro

Stefan Just

Stefan Peters

Markus Ostermeier

Janus Schreiber Larsen

Oliver Hucke

Florian Binder

Dietrich Keppler

Radoslaw Lipinski

Alexandre Perera

Joerg Koenig

Florian Montel

Jörg König

The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAreceptors containing the &#x3b1;5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Difluoromethyl-phenyl triazoles

3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.

Somatostatin receptor subtype 4 (SSTR4) agonists

Described is a double-transfected cell line containing (a) a DNA sequence encoding an uptake transporter for organic anions, preferably OATP8, operatively linked with a promoter and (b) a DNA sequence encoding an export pump for organic anions or anionic conjugates, preferably the multidrug resistance protein 2 (MRP2), operatively linked with a promoter. Moreover, various uses of said cell line are described, preferably its use for the identification of transport inhibitors, e.g. drug candidates.

Double-transfected cell line useful for the identification of transport inhibitors

Growing community of inventors

Biberach an der Riss, Germany

Yunhai Cui